|
To enter a simulation, please read the information below, acknowledge that you have read the information by checking the box at the bottom of this page, and click the Continue button.
An Evaluation of Restless Leg Syndrome (RLS)
Cases Developed by Expert Faculty
John Harrington, MD
Assistant Professor
Sleep Division, Department of Medicine
National Jewish Health
Teofilo Lee-Chiong, MD
Professor of Medicine and
Head, Division of Sleep Medicine
National Jewish Health
Daniel Smith, MD
Assistant Professor
Pulmonary Division, Department of Medicine
National Jewish Health
Release Date
December 7, 2009
Term of Approval
December 7, 2009 through December 7, 2010
Requests for credit must be received no later than December 7, 2010.
Target Audience
This activity was developed for Primary Care Physicians (PCPs) nationally.
Learning Objectives
Following completion of this series of case simulations, participants should be able to:
- To recognize the clinical manifestations of Restless Leg Syndrome (RLS)
- To understand the proposed pathophysiology of RLS
- To recognize diagnosis challenges of RLS
- To develop a successful therapy program for RLS
Accreditation Statement
National Jewish Health is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
Designation Statement
National Jewish Health designates this educational activity for a maximum of 1 AMA PRA Category 1 Credit™. Physicians should only claim credit commensurate with the extent of their participation in the activity.
This program is sponsored by National Jewish Health.
Disclosure Information Listed for CME Content Development and Approval Committee and Participating Program Faculty
In accordance with the Accreditation Council for Continuing Medical Education, National Jewish Health requires that all program faculty, content developers, CME approval committee, and medical writers in a position to control the content of this activity are expected to disclose any or no significant financial interest or other relationship with any proprietary entity producing health care goods or services, with the exemption of non-profit or governmental organizations and non-health care related companies. Our goal is to ensure that there is no compromise of the ethical relationship that exists between those in a position to control the content of the activity and those attending the activity and their respective professional duties.
Significant financial interest is defined as receiving, or in the past twelve months having received, a salary, royalty, intellectual property rights, consulting fee, honoraria, ownership interest (e.g., stocks, stock options or other ownership interest, excluding diversified mutual funds), or other financial benefit. Financial benefits are usually associated with roles such as employment, management position, independent contractor (including contracted research), consulting, speaking and teaching, membership on advisory committees or review panels, board membership, and other activities from which remuneration is received or expected.
All CME Educational Activities sponsored by National Jewish Health are reviewed by our faculty CME committee to ensure a balanced and evidence-based presentation. Any potential conflict of interest among program faculty has been identified and resolved according to ACCME guidelines.
Faculty Disclosures
In accordance with the Accreditation Council for Continuing Medical Education, National Jewish Health requires that all persons in a position to control the content of a CME activity, including the CME review committee disclose all significant financial interest with commercial interests including the review committee.
Key
A - Advisory Board B - Board of Directors C- Consultant E- Employee
F - Founder I - Investigator O - Other SP- Speaker SH - Stockholder
John Harrington, MD
I – Actelion, Breathe
Teoflio Lee-Chiong, MD
C – DievielNutrisystems, Covidien
Harold Nelson, MD
C – Abbott, AstraZeneca, Boehringer-Ingelheim, Dey, L.P., Dynavax Technologies, Dyson, Genentech, GlaxoSmithKline, Johnson & Johnson, MediciNova, Novartis, Schering- Plough, Sepracor, Teva
I – Altana, AstraZeneca, Boehringer-Ingelheim, Ception, Genentech, Novartis, Schering-Plough, Sepracor, Wyeth
SP – AstraZeneca , GlaxoSmithKline
David Smith, MD
Has no significant financial interest to report
Disclaimer
The information provided during this CME activity is for continuing education purposes only and is not meant to substitute for the independent medical judgment of a physician relative to diagnostic and treatment options of a specific patient's medical condition.
Hardware/Software Requirements
The simulation requires Microsoft Internet Explorer 6.0 or higher (get IE) or Mozilla Firefox version 2.0 or higher (get Firefox). Certain activities may require additional software to view multimedia, presentation, or printable versions of their content. There are no specific hardware requirements.
|
